Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Tarun K. Garg, PhD, Junaid Khan, Susann Szmania, Amy D Greenway, Joshuah D Lingo, Amberly Moreno-Bost, Katie Stone, Antje Hoering, PhD, Emily Woods, Bijay Nair, MD, William Bellamy, PhD, Dario Campana, MD, PhD, Shmuel Yaccoby, PhD, Bart Barlogie, MD, Ph.D, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 2918.

https://doi.org/10.1182/blood.V118.21.2918.2918

Published: 2011

Journal Articles

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Tarun K. Garg, PhD, Susann Szmania, BS, Paul Malbrough, BS, Charles Ekworomadu, MS, Katie Stone, BS, Amberly Moreno-Bost, BS, Emily Woods, BS, Jumei Shi, MD, PhD, Shmuel Yaccoby, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2009) 114 (22): 953.

https://doi.org/10.1182/blood.V114.22.953.953

Published: 2009

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

Journal Articles

Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

Tarun K. Garg, PhD, Susann Szmania, BS, Jumei Shi, MD, PhD, Katie Stone, BS, Amberly Moreno-Bost, BS, Paul Malbrough, BS, Dario Campana, MD., PhD, Bart Barlogie, MD, PhD, Daniel Afar, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 3666.

https://doi.org/10.1182/blood.V112.11.3666.3666

Published: 2008

Journal Articles

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

Amberly Moreno-Bost, BS, Susann Szmania, BS, Katie Stone, BS, Jumei Shi, MD, PhD, Tarun K. Garg, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Hugh Grant Prentice, MD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 3674.

https://doi.org/10.1182/blood.V112.11.3674.3674

Published: 2008

Journal Articles

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

Sacha Gnjatic, PhD, Susann Szmania, BS, Amberly Moreno, BS, M. Cottler-Fox, MD, John Shaughnessy, MD, Bart Barlogie, MD, PhD, Lloyd Old, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 2197.

https://doi.org/10.1182/blood.V106.11.2197.2197

Published: 2005

Journal Articles

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

Frits van Rhee, Susann M. Szmania, Fenghuang Zhan, Sushil K. Gupta, Mindy Pomtree, Pei Lin, Ramesh B. Batchu, Amberly Moreno, Guilio Spagnoli, John Shaughnessy, Guido Tricot

Blood (2005) 105 (10): 3939–3944.

https://doi.org/10.1182/blood-2004-09-3707

Published: 2005

Journal Articles

NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, Amberly Moreno, BS, Ramesh Batchu, PhD, Mindy Pomtree, BS, Nancy Rosen, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Guido J. Trico, MD, PhD

Blood (2004) 104 (11): 2454.

https://doi.org/10.1182/blood.V104.11.2454.2454

Published: 2004

Journal Articles

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, Mindy Pomtree, Frank Zhan, Amberly Moreno, BS, Nancy Rosen, Michele Fox, MD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD, Ramesh Batchu, PhD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 2464.

https://doi.org/10.1182/blood.V104.11.2464.2464

Published: 2004

Journal Articles

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Susann Szmania, BS, Michele Cottler-Fox, MD, Nancy Rosen, BS, Sanjaya Viswamitra, MD, Amberly Moreno, BS, Mindy Pomtree, BS, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2004) 104 (11): 2920.

https://doi.org/10.1182/blood.V104.11.2920.2920

Published: 2004

NARROW

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only